{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-25-000043","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.569139+00:00","generated_at":"2026-05-22T04:04:40.628230+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Skye Bioscience Q1 net loss $11.1M; nimacimab combo shows >30% weight loss in preclinical","bullets":["Net loss for Q1 2025 was $11.1M ($2.2M non-cash share-based comp) vs $5.0M in Q1 2024.","Cash and short-term investments total $59.2M; expected to fund operations through at least Q1 2027.","Preclinical DIO model: nimacimab + tirzepatide achieved >30% weight loss; nimacimab alone 23.5% comparable to monlunabant and tirzepatide alone.","In vitro data shows superior potency of peripherally restricted nimacimab vs small molecule monlunabant under pathological CB1 agonist levels.","Top-line data from Phase 2a CBeyond study of nimacimab expected late Q3/early Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-25-000043","json":"https://secwatch.observer/filing/0001516551-25-000043.json","markdown":"https://secwatch.observer/filing/0001516551-25-000043.md","text":"https://secwatch.observer/filing/0001516551-25-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655125000043/0001516551-25-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655125000043/skye-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:04:40.628230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}